285 related articles for article (PubMed ID: 35062890)
1. Characteristics associated with HIV and hepatitis C seroprevalence among sexual and injecting partners of HIV positive persons who inject drugs in Nairobi and coastal Kenya.
Sambai BC; Kingston H; Monroe-Wise A; Mbogo L; Juma E; Ludwig-Barron N; Guthrie BL; Bukusi D; Chohan BH; Scott J; Bosire R; Dunbar M; Macharia P; Masyuko S; Sinkele W; Herbeck JT; Farquhar C
BMC Infect Dis; 2022 Jan; 22(1):73. PubMed ID: 35062890
[TBL] [Abstract][Full Text] [Related]
2. Rapid situational assessment of people who inject drugs (PWID) in Nairobi and coastal regions of Kenya: a respondent driven sampling survey.
Oguya FO; Kenya PR; Ongecha F; Mureithi P; Musyoka H; Muraguri N; Mundia B; Angira C; Shose M; Basheeb TA; Mohamed AA; Oyore JP; Ochieng OG; Dida GO; Abdalla S; Abdool R
BMC Public Health; 2021 Aug; 21(1):1549. PubMed ID: 34391389
[TBL] [Abstract][Full Text] [Related]
3. Prevalence, estimated incidence, risk behaviours, and genotypic distribution of hepatitis C virus among people who inject drugs accessing harm-reduction services in Kenya: a retrospective cohort study.
Akiyama MJ; Cleland CM; Lizcano JA; Cherutich P; Kurth AE
Lancet Infect Dis; 2019 Nov; 19(11):1255-1263. PubMed ID: 31540840
[TBL] [Abstract][Full Text] [Related]
4. Prevalence and correlates of violence among sexual and injecting partners of people who inject drugs living with HIV in Kenya: a cross-sectional study.
Aung SWKH; Kingston H; Mbogo LW; Sambai B; Monroe-Wise A; Ludwig-Barron NT; Bukusi D; Sinkele W; Gitau E; Masyuko S; Herbeck JT; Farquhar C; Guthrie BL
Harm Reduct J; 2023 Nov; 20(1):164. PubMed ID: 37919736
[TBL] [Abstract][Full Text] [Related]
5. High variability of HIV and HCV seroprevalence and risk behaviours among people who inject drugs: results from a cross-sectional study using respondent-driven sampling in eight German cities (2011-14).
Wenz B; Nielsen S; Gassowski M; Santos-Hövener C; Cai W; Ross RS; Bock CT; Ratsch BA; Kücherer C; Bannert N; Bremer V; Hamouda O; Marcus U; Zimmermann R;
BMC Public Health; 2016 Sep; 16(1):927. PubMed ID: 27595567
[TBL] [Abstract][Full Text] [Related]
6. Prevalence and risk factors associated with HIV/hepatitis B and HIV/hepatitis C co-infections among people who inject drugs in Mozambique.
Semá Baltazar C; Boothe M; Kellogg T; Ricardo P; Sathane I; Fazito E; Raymond HF; Temmerman M; Luchters S
BMC Public Health; 2020 Jun; 20(1):851. PubMed ID: 32493347
[TBL] [Abstract][Full Text] [Related]
7. High prevalence of HIV, HBsAg and anti-HCV positivity among people who injected drugs: results of the first bio-behavioral survey using respondent-driven sampling in two urban areas in Mozambique.
Semá Baltazar C; Horth R; Boothe M; Sathane I; Young P; Chitsondzo Langa D; Condula M; Ricardo H; Dengo Baloi L; Cummings B; Schaad N; Gouveia L; Teodoro E; Raymond HF
BMC Infect Dis; 2019 Dec; 19(1):1022. PubMed ID: 31791273
[TBL] [Abstract][Full Text] [Related]
8. Understanding hepatitis B, hepatitis C and HIV among people who inject drugs in South Africa: findings from a three-city cross-sectional survey.
Scheibe A; Young K; Moses L; Basson RL; Versfeld A; Spearman CW; Sonderup MW; Prabdial-Sing N; Manamela J; Puren AJ; Rebe K; Hausler H
Harm Reduct J; 2019 Apr; 16(1):28. PubMed ID: 30975139
[TBL] [Abstract][Full Text] [Related]
9. SARS-CoV-2 antibody prevalence, correlates, and access to harm reduction services among people who inject drugs living with and without HIV and their partners in Kenya.
Doshi S; Kingston H; Tseng AS; Chohan BH; Sambai B; Guthrie BL; Monroe-Wise A; Mbogo LW; Masyuko S; Tram KH; Sinkele W; Macharia P; Bukusi D; Herbeck JT; Farquhar C
Harm Reduct J; 2023 Feb; 20(1):21. PubMed ID: 36823596
[TBL] [Abstract][Full Text] [Related]
10. High regional variability of HIV, HCV and injecting risks among people who inject drugs in Poland: comparing a cross-sectional bio-behavioural study with case-based surveillance.
Rosińska M; Sierosławski J; Wiessing L
BMC Infect Dis; 2015 Feb; 15():83. PubMed ID: 25879904
[TBL] [Abstract][Full Text] [Related]
11. Modelling the impact of HIV and hepatitis C virus prevention and treatment interventions among people who inject drugs in Kenya.
Stone J; Fraser H; Walker JG; Mafirakureva N; Mundia B; Cleland C; Bartilol K; Musyoki H; Waruiru W; Ragi A; Bhattacharjee P; Chhun N; Lizcano J; Akiyama MJ; Cherutich P; Wisse E; Kurth A; Luhmann N; Vickerman P
AIDS; 2022 Dec; 36(15):2191-2201. PubMed ID: 36111533
[TBL] [Abstract][Full Text] [Related]
12. Cross-border injection drug use and HIV and hepatitis C virus seropositivity among people who inject drugs in San Diego, California.
Horyniak D; Wagner KD; Armenta RF; Cuevas-Mota J; Hendrickson E; Garfein RS
Int J Drug Policy; 2017 Sep; 47():9-17. PubMed ID: 28683432
[TBL] [Abstract][Full Text] [Related]
13. Underreported injection drug use and its potential contribution to reported increase in sexual transmission of HIV in Kazakhstan and Kyrgyzstan.
Deryabina AP; Patnaik P; El-Sadr WM
Harm Reduct J; 2019 Jan; 16(1):1. PubMed ID: 30611251
[TBL] [Abstract][Full Text] [Related]
14. HIV Prevalence, Estimated Incidence, and Risk Behaviors Among People Who Inject Drugs in Kenya.
Kurth AE; Cleland CM; Des Jarlais DC; Musyoki H; Lizcano JA; Chhun N; Cherutich P
J Acquir Immune Defic Syndr; 2015 Dec; 70(4):420-7. PubMed ID: 26226249
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of assisted partner services for people who inject drugs in Kenya to identify partners living with HIV and hepatitis C virus infection: a prospective cohort study.
Monroe-Wise A; Mbogo L; Sambai B; Ludwig-Barron N; Guthrie BL; Bukusi D; Chohan BH; Masyuko S; Scott J; Juma E; Macharia P; Kingston H; Sinkele W; Gitau E; Bosire R; Musyoki H; Herbeck J; Farquhar C
Lancet Glob Health; 2024 May; 12(5):e859-e867. PubMed ID: 38614633
[TBL] [Abstract][Full Text] [Related]
16. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review.
Degenhardt L; Peacock A; Colledge S; Leung J; Grebely J; Vickerman P; Stone J; Cunningham EB; Trickey A; Dumchev K; Lynskey M; Griffiths P; Mattick RP; Hickman M; Larney S
Lancet Glob Health; 2017 Dec; 5(12):e1192-e1207. PubMed ID: 29074409
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of HIV/Hepatitis C Virus Co-Infection and Injection Risk Correlations in People Who Inject Drugs in Colombia: A Cross-Sectional Study Using Respondent Driven Sampling.
Toro-Tobón D; Berbesi-Fernández D
Subst Use Misuse; 2020; 55(3):414-423. PubMed ID: 31691646
[No Abstract] [Full Text] [Related]
18. Occupational roles and risks of community-embedded peer educators providing HIV, hepatitis C and harm reduction services to persons who inject drugs in Nairobi, Kenya.
Masese LN; Ludwig-Barron NT; Mbogo L; Guthrie BL; Musyoki H; Bukusi D; Sinkele W; Gitau E; Farquhar C; Monroe-Wise A
PLoS One; 2022; 17(12):e0278210. PubMed ID: 36454881
[TBL] [Abstract][Full Text] [Related]
19. Prevalence of HIV and other infections and injection behaviours among people who inject drugs in Addis Ababa, Ethiopia.
Demissie M; Johnston LG; Muleta M; Desyebelew D; Belete W; G/Egxiabehre A; Gezahegn N; Kassa D; Aseffa Y
Afr J AIDS Res; 2018 Sep; 17(3):259-264. PubMed ID: 30319040
[TBL] [Abstract][Full Text] [Related]
20. Seroprevalence and risk factors associated with hepatitis C: a cross-sectional study of persons who inject drugs in Puerto Rico, 2018.
Colón-López V; Alvelo-Fernández PM; Centeno-Alvarado N; Agudelo Salas IY; Rolón Colón Y; Pabón Martínez M; Rodríguez-Lebrón JL; Reyes-Pulliza JC
BMC Public Health; 2023 Apr; 23(1):704. PubMed ID: 37072733
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
